Influence of Natriuretic Peptide Receptor-1 on Survival and Cardiac Hypertrophy During Development

Overview

Journal Biochim Biophys Acta

Specialties Biochemistry
Biophysics

Date 2009 Sep 29

PMID 19782130

Citations 17

Authors

Nicola J A Scott

Leigh J Ellmers

John G Lainchbury

Nobuyo Maeda

Oliver Smithies

A Mark Richards

Vicky A Cameron

Affiliations

Soon will be listed here.

Abstract

The heart adapts to an increased workload through the activation of a hypertrophic response within the cardiac ventricles. This response is characterized by both an increase in the size of the individual cardiomyocytes and an induction of a panel of genes normally expressed in the embryonic and neonatal ventricle, such as atrial natriuretic peptide (ANP). ANP and brain natriuretic peptide (BNP) exert their biological actions through activation of the natriuretic peptide receptor-1 (Npr1). The current study examined mice lacking Npr1 (Npr1(-/-)) activity and investigated the effects of the absence of Npr1 signaling during cardiac development on embryo viability, cardiac structure and gene and protein expression. Npr1(-/-)embryos were collected at embryonic day (ED) 12.5, 15.5 and neonatal day 1 (ND 1). Npr1(-/-)embryos occurred at the expected Mendelian frequency at ED 12.5, but knockout numbers were significantly decreased at ED 15.5 and ND 1. There was no indication of cardiac structural abnormalities in surviving embryos. However, Npr1(-/-)embryos exhibited cardiac enlargement (without fibrosis) from ED 15.5 as well as significantly increased ANP mRNA and protein expression compared to wild-type (WT) mice, but no concomitant increase in expression of the hypertrophy-related transcription factors, Mef2A, Mef2C, GATA-4, GATA-6 or serum response factor (SRF). However, there was a significant decrease in Connexin-43 (Cx43) gene and protein expression at mid-gestation in Npr1(-/-)embryos. Our findings suggest that the mechanism by which natriuretic peptide signaling influences cardiac development in Npr1(-/-) mice is distinct from that seen during the development of pathological cardiac hypertrophy and fibrosis. The decreased viability of Npr1(-/-)embryos may result from a combination of cardiomegaly and dysregulated Cx43 protein affecting cardiac contractility.

Citing Articles

The Impact of Natriuretic Peptides on Heart Development, Homeostasis, and Disease.

Giovou A, Gladka M, Christoffels V Cells. 2024; 13(11.

PMID: 38891063 PMC: 11172276. DOI: 10.3390/cells13110931.

Natriuretic Peptides: It Is Time for Guided Therapeutic Strategies Based on Their Molecular Mechanisms.

Gallo G, Rubattu S, Autore C, Volpe M Int J Mol Sci. 2023; 24(6).

PMID: 36982204 PMC: 10049669. DOI: 10.3390/ijms24065131.

Genetic Disruption of Guanylyl Cyclase/Natriuretic Peptide Receptor-A Triggers Differential Cardiac Fibrosis and Disorders in Male and Female Mutant Mice: Role of TGF-β1/SMAD Signaling Pathway.

Subramanian U, Ramasamy C, Ramachandran S, Oakes J, Gardner J, Pandey K Int J Mol Sci. 2022; 23(19).

PMID: 36232788 PMC: 9569686. DOI: 10.3390/ijms231911487.

Guanylyl cyclase-A phosphorylation decreases cardiac hypertrophy and improves systolic function in male, but not female, mice.

Wagner B, Robinson J, Healy C, Gauthier M, Dickey D, Yee S FASEB J. 2021; 36(1):e22069.

PMID: 34859913 PMC: 8826535. DOI: 10.1096/fj.202100600RRR.

Molecular Signaling Mechanisms and Function of Natriuretic Peptide Receptor-A in the Pathophysiology of Cardiovascular Homeostasis.

Pandey K Front Physiol. 2021; 12:693099.

PMID: 34489721 PMC: 8416980. DOI: 10.3389/fphys.2021.693099.

References

Leu M, Ehler E, Perriard J . Characterisation of postnatal growth of the murine heart. Anat Embryol (Berl). 2001; 204(3):217-24. DOI: 10.1007/s004290100206. View

Takayanagi R, Imada T, Inagami T . Synthesis and presence of atrial natriuretic factor in rat ventricle. Biochem Biophys Res Commun. 1987; 142(2):483-8. DOI: 10.1016/0006-291x(87)90300-7. View

Day M, Schwartz D, Wiegand R, Stockman P, Brunnert S, Tolunay H . Ventricular atriopeptin. Unmasking of messenger RNA and peptide synthesis by hypertrophy or dexamethasone. Hypertension. 1987; 9(5):485-91. DOI: 10.1161/01.hyp.9.5.485. View

Severs N, Coppen S, Dupont E, Yeh H, Ko Y, Matsushita T . Gap junction alterations in human cardiac disease. Cardiovasc Res. 2004; 62(2):368-77. DOI: 10.1016/j.cardiores.2003.12.007. View

Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T . Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation. 2002; 106(13):1722-8. DOI: 10.1161/01.cir.0000029923.57048.61. View

Horsthuis T, Houweling A, Habets P, de Lange F, Azzouzi H, Clout D . Distinct regulation of developmental and heart disease-induced atrial natriuretic factor expression by two separate distal sequences. Circ Res. 2008; 102(7):849-59. DOI: 10.1161/CIRCRESAHA.107.170571. View

Lang C, Choy A, Turner K, Tobin R, Coutie W, Struthers A . The effect of intravenous saline loading on plasma levels of brain natriuretic peptide in man. J Hypertens. 1993; 11(7):737-41. DOI: 10.1097/00004872-199307000-00009. View

Ellmers L, Knowles J, Kim H, SMITHIES O, Maeda N, Cameron V . Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol. 2002; 283(2):H707-14. PMC: 4321891. DOI: 10.1152/ajpheart.00677.2001. View

Espiner E, Richards A, Yandle T, Nicholls M . Natriuretic hormones. Endocrinol Metab Clin North Am. 1995; 24(3):481-509. View

10.

Knowles J, Esposito G, Mao L, Hagaman J, Fox J, SMITHIES O . Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest. 2001; 107(8):975-84. PMC: 199554. DOI: 10.1172/JCI11273. View

11.

Porrello E, Bell J, Schertzer J, Curl C, McMullen J, Mellor K . Heritable pathologic cardiac hypertrophy in adulthood is preceded by neonatal cardiac growth restriction. Am J Physiol Regul Integr Comp Physiol. 2009; 296(3):R672-80. DOI: 10.1152/ajpregu.90919.2008. View

12.

Kishimoto I, Rossi K, Garbers D . A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci U S A. 2001; 98(5):2703-6. PMC: 30202. DOI: 10.1073/pnas.051625598. View

13.

Molkentin J, Dorn 2nd G . Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001; 63:391-426. DOI: 10.1146/annurev.physiol.63.1.391. View

14.

Vellaichamy E, Sommana N, Pandey K . Reduced cGMP signaling activates NF-kappaB in hypertrophied hearts of mice lacking natriuretic peptide receptor-A. Biochem Biophys Res Commun. 2005; 327(1):106-11. DOI: 10.1016/j.bbrc.2004.11.153. View

15.

Jaekle R, Sheikh A, BERRY D, Washburn L, Rose J . Hemodynamic and hormonal responses to atrial distension in the ovine fetus. Am J Obstet Gynecol. 1995; 173(3 Pt 1):694-701. DOI: 10.1016/0002-9378(95)90325-9. View

16.

Walther T, Stepan H, Faber R . Dual natriuretic peptide response to volume load in the fetal circulation. Cardiovasc Res. 2001; 49(4):817-9. DOI: 10.1016/s0008-6363(00)00303-5. View

17.

Lopez M, Wong S, Kishimoto I, Dubois S, Mach V, Friesen J . Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995; 378(6552):65-8. DOI: 10.1038/378065a0. View

18.

Eckardt D, Kirchhoff S, Kim J, Degen J, Theis M, Ott T . Cardiomyocyte-restricted deletion of connexin43 during mouse development. J Mol Cell Cardiol. 2006; 41(6):963-71. DOI: 10.1016/j.yjmcc.2006.07.017. View

19.

Christoffels V, Habets P, Franco D, Campione M, de Jong F, Lamers W . Chamber formation and morphogenesis in the developing mammalian heart. Dev Biol. 2000; 223(2):266-78. DOI: 10.1006/dbio.2000.9753. View

20.

Oliver P, John S, PURDY K, Kim R, Maeda N, Goy M . Natriuretic peptide receptor 1 expression influences blood pressures of mice in a dose-dependent manner. Proc Natl Acad Sci U S A. 1998; 95(5):2547-51. PMC: 19408. DOI: 10.1073/pnas.95.5.2547. View